Table 2.
Reported malignant hypercalcemia in seminomas
| Author (*) | Ca+ | PTH | PTHrP | 25D | 1,25D | Tx | Ca + after Tx. | Outcome |
|---|---|---|---|---|---|---|---|---|
| King [6] |
15.4 |
NS |
NS |
NS |
NS |
Orchiectomy |
NL |
NED 10 mo. |
| Metcalfe [7] |
15.8 |
NS |
NS |
NS |
NS |
GC + RT |
NL |
NED 8 mo. |
| Grote [8] |
15.4 |
10.0 |
NS |
24.0 |
112 |
BEP |
NL |
NED 2 yr. |
| Da Silva [9] |
12.7 |
NL |
NS |
NS |
NS |
NSCT |
NL |
Adenophaty |
| Da Silva [9] |
18.5 |
NS |
NS |
NS |
NS |
BEP |
NL |
NED 2 mo. |
| Da Silva [9] |
20.1 |
NS |
NS |
NS |
NS |
NSCT |
NL |
NED 4 mo. |
| Da Silva [9] |
16.4 |
0.3 |
NS |
NS |
79 |
BEP |
NL |
Improved after CT |
| This report | 14.7 | ≤3.0 | 35.0 | 22.0 | 212 | BEP | NL | NED 8 mo. |
(*) Reference.
Ca+, Calcium (mg/dl); PTH, parathyroid hormone; PTHrP, parathyroid hormone related protein; 25D, 25, Hydroxyvitamin D; 1,25D, 1,25-Dihydroxyvitamin D; Tx, treatment; NS, not stated; NL, normal; NED, not evidence of disease; BEP, bleomycin, etoposide and cisplatinum; NSCT, not specified chemotherapy; CT, chemotherapy.